허셉틴 시장 보고서(2025년)

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, Herceptin inhibits tumor cell proliferation and marks them for destruction by the immune system.

The main products of Herceptin include biologics and biosimilars. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The key payers include commercial, private, and public sectors, with applications in the treatment of breast and gastric cancers. Treatment is distributed through various channels, such as hospital pharmacies and specialty pharmacies.

The herceptin market research report is one of a series of new reports from The Business Research Company that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The herceptin market size has grown strongly in recent years. It will grow from$7.10 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to regulatory approvals, the rising incidence of breast cancer, advancements in monoclonal antibody technology, positive clinical trial outcomes, and increasing healthcare expenditure.

The herceptin market size is expected to see strong growth in the next few years. It will grow to$9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, improved healthcare access in emerging markets, ongoing research and development in oncology, and the rising prevalence of HER2-positive cancers. Key trends in the forecast period include the development of antibody-drug conjugates, advancements in biosimilar formulations, the integration of AI in drug discovery, personalized medicine approaches, and improvements in drug delivery systems.

The growing incidence of breast cancer is expected to drive the expansion of the Herceptin market. Breast cancer, which develops in the cells of the breast, typically starts in the milk ducts or lobules, and includes types such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer cases is partly attributed to lifestyle factors such as higher alcohol consumption, poor diet, and a lack of physical activity, all of which contribute to a higher risk. As more individuals, particularly those diagnosed with HER2-positive breast cancer, are seeking treatment, the demand for effective targeted therapies such as Herceptin continues to grow. For instance, in January 2025, the American Cancer Society projected approximately 319,750 new cases of breast cancer in the U.S. with 42,680 expected deaths. Therefore, the increasing incidence of breast cancer is fueling the growth of the Herceptin market.

Leading companies in the Herceptin market are developing innovative biosimilar products to improve patient access and enhance therapeutic outcomes for HER2-positive cancers. Biosimilars are highly similar versions of approved biologic drugs, developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI provide patients with a cost-effective treatment option while maintaining comparable efficacy and safety to the original biologic drug.

In December 2022, Celltrion Inc., a South Korea-based biopharmaceutical company, merged with Celltrion Healthcare Co. to enhance its cost competitiveness and diversify its product pipeline. This merger is designed to streamline operations, boost research investments, and simplify the company's structure. Celltrion Healthcare Co., known for developing the Herceptin biosimilar Herzuma (trastuzumab-pkrb), which was approved by the FDA, is now positioned to further strengthen its global biopharma presence following this strategic merger.

Major players in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy's Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., and Prestige Biopharma Pte Ltd.

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herceptin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herceptin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on herceptin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for herceptin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herceptin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Biologic; Biosimilar
• 2) By Application: Breast Cancer; Gastric Cancer
• 3) By Payer: Commercial And Private; Public
• 4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy
• Subsegments:
• 1) By Biologic: Intravenous (IV) Biologics; Subcutaneous (SC) Biologic
• 2) By Biosimilar: Intravenous (IV) Biosimilars; Subcutaneous (SC) Biosimilars
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; GlaxoSmithKline plc; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Herceptin Market Characteristics

3. Herceptin Market Trends And Strategies

4. Herceptin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Herceptin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Herceptin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Herceptin Market Growth Rate Analysis
• 5.4. Global Herceptin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Herceptin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Herceptin Total Addressable Market (TAM)

6. Herceptin Market Segmentation

• 6.1. Global Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologic
• Biosimilar
• 6.2. Global Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Stomach Or Gastric Cancer
• 6.3. Global Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Commercial And Private
• Public
• 6.4. Global Herceptin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Specialty Pharmacy
• 6.5. Global Herceptin Market, Sub-Segmentation Of Biologic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Biologics
• Subcutaneous (SC) Biologic
• 6.6. Global Herceptin Market, Sub-Segmentation Of Biosimilar, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Biosimilars
• Subcutaneous (SC) Biosimilars

7. Herceptin Market Regional And Country Analysis

• 7.1. Global Herceptin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Herceptin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Herceptin Market

• 8.1. Asia-Pacific Herceptin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Herceptin Market

• 9.1. China Herceptin Market Overview
• 9.2. China Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Herceptin Market

• 10.1. India Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Herceptin Market

• 11.1. Japan Herceptin Market Overview
• 11.2. Japan Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Herceptin Market

• 12.1. Australia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Herceptin Market

• 13.1. Indonesia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Herceptin Market

• 14.1. South Korea Herceptin Market Overview
• 14.2. South Korea Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Herceptin Market

• 15.1. Western Europe Herceptin Market Overview
• 15.2. Western Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Herceptin Market

• 16.1. UK Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Herceptin Market

• 17.1. Germany Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Herceptin Market

• 18.1. France Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Herceptin Market

• 19.1. Italy Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Herceptin Market

• 20.1. Spain Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Herceptin Market

• 21.1. Eastern Europe Herceptin Market Overview
• 21.2. Eastern Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Herceptin Market

• 22.1. Russia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Herceptin Market

• 23.1. North America Herceptin Market Overview
• 23.2. North America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Herceptin Market

• 24.1. USA Herceptin Market Overview
• 24.2. USA Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Herceptin Market

• 25.1. Canada Herceptin Market Overview
• 25.2. Canada Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Herceptin Market

• 26.1. South America Herceptin Market Overview
• 26.2. South America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Herceptin Market

• 27.1. Brazil Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Herceptin Market

• 28.1. Middle East Herceptin Market Overview
• 28.2. Middle East Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Herceptin Market

• 29.1. Africa Herceptin Market Overview
• 29.2. Africa Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Herceptin Market Competitive Landscape And Company Profiles

• 30.1. Herceptin Market Competitive Landscape
• 30.2. Herceptin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Herceptin Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd
• 31.3. Boehringer Ingelheim GmbH
• 31.4. Genentech Inc.
• 31.5. Dr. Reddy's Laboratories
• 31.6. Celltrion Healthcare
• 31.7. Mundipharma
• 31.8. Biocon Limited
• 31.9. Bio-Techne Corporation
• 31.10. Samsung Bioepis Co Ltd
• 31.11. AryoGen Pharmed
• 31.12. InvivoGen
• 31.13. Abnova Corporation
• 31.14. Shanghai Henlius Biotech Inc
• 31.15. Prestige Biopharma Pte Ltd.

32. Global Herceptin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Herceptin Market

34. Recent Developments In The Herceptin Market

35. Herceptin Market High Potential Countries, Segments and Strategies

• 35.1 Herceptin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Herceptin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Herceptin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer